^
Association details:
| Biomarker: | BRAF K601E |
|---|---|
| Cancer: | Melanoma |
| Drug: | Mekinist (trametinib) (MEK inhibitor) + sorafenib (Multi-tyrosine kinase inhibitor, pan-RAF inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
5348 / 30 - Targeting MEK, alone and in combination with BRAF, in metastatic BRAFK601E-mutated melanoma
Published date:
03/15/2023
Excerpt:
Melanoma cell line (MeWo) was transfected with doxycycline-inducible vector encoding wild-type or K601E-mutant BRAF. Subsequently, cells or xenograft-bearing mice were treated with trametinib, dabrafenib plus trametinib or sorafenib plus trametinib. Compared with BRAF WT, MTT assay demonstrated that BRAF K601E cells were more sensitive towards drug treatment. The effects of combined treatment were more profound. Tumorigenicity assay showed that trametinib treatment inhibited tumor growth of BRAFK601E xenografts.
